Healthcare [ 5/13 ] | Health Information Services [ 89/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0 Increased by +100% | -0.17 Increased by +100% |
| Feb 29, 24 | 0 Increased by +100% | -0.21 Increased by +100% |
| Nov 9, 23 | -0.18 Decreased by -123.68% | -0.19 Increased by +5.26% |
| Aug 10, 23 | -0.16 Increased by +56.27% | -0.2 Increased by +20% |
| May 11, 23 | -0.21 Decreased by -62.69% | -0.22 Increased by +3.86% |
| Mar 7, 23 | -0.72 Decreased by -1.1 K% | -0.31 Decreased by -132.26% |
| Nov 10, 22 | 0.76 Increased by +7.7 K% | -0.25 Increased by +404% |
| Aug 12, 22 | -0.37 Decreased by -3.56 K% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 702 K Increased by +756.1% | -15.88 M Decreased by -112.08% | Decreased by -2.26 K% Decreased by -101.41% |
| Jun 30, 23 | 114 K Increased by +78.13% | -11.76 M Increased by +47.63% | Decreased by -10.31 K% Increased by +70.6% |
| Mar 31, 23 | 113 K Increased by +71.21% | -22.93 M Decreased by -4.96% | Decreased by -20.29 K% Increased by +38.7% |
| Dec 31, 22 | 111 K Decreased by -31.06% | -16.82 M Increased by +14.26% | Decreased by -15.15 K% Decreased by -24.37% |
| Sep 30, 22 | 82 K Decreased by -47.1% | 131.47 M Increased by +824.89% | Increased by +160.33 K% Increased by +1.47 K% |
| Jun 30, 22 | 64 K Increased by +N/A% | -22.45 M Decreased by -15.7 M% | Decreased by -35.08 K% - |
| Mar 31, 22 | 66 K Increased by +N/A% | -21.84 M Decreased by N/A% | Decreased by -33.09 K% - |
| Dec 31, 21 | 161 K Increased by +61% | -19.61 M Decreased by -157.23% | Decreased by -12.18 K% Decreased by -59.77% |
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.